Answers are grounded in this paper and cite their sources.
Case report shows disitamab vedotin achieves durable partial response in HER2 2+/FISH- bladder cancer, suggesting new treatment options.
Disitamab Vedotin achieved durable partial response (> 8 months PFS) in advanced HER2 2+/FISH‐ bladder cancer after first‐line chemo‐immunotherapy progression. This case provides real‐world evidence that disitamab vedotin may benefit HER2 2+/FISH‐ patients, supporting broader HER2 testing and treatment consideration in this subset.
No takes yet. Share an insight, caveat, or question.
Jin et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: